Perfectus Biomed Group, now part of NAMSA are global leaders in customized microbiological testing. In October 2022, Perfectus Biomed Group was acquired by NAMSA, a leading MedTech-focused Contract Research Organization (CRO) providing full continuum MedTech development solutions. Founded in 1967, NAMSA is the pioneer of the medical device testing industry and has expanded over the years to offer full development lifecycle solutions to Sponsors worldwide. These services include laboratory and preclinical testing; quality, reimbursement, and regulatory consulting; clinical research solutions; IVD services and more.

Perfectus Biomed Group has extensive experience in developing ‘fit for purpose’ experiments that truly mimic ‘real-life’ scenarios. With a unique expertise in customized assays including, advanced wound care studies, viral inactivation, biofilm testing and atypical organisms, we support clients at all stages of their product development, from initial characterization of technologies and generation of data for regulatory submissions, to the provision of evidence to substantiate marketing claims for finished products and technologies. Perfectus can perform GLP-compliant testing and is a UKAS accredited ISO 17025 contract testing laboratory.